Oct 8 (Reuters) - Aardvark Therapeutics Inc AARD.O:
AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME
AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME
AARDVARK THERAPEUTICS INC - TRIAL ELIGIBILITY AGE CHANGED FROM 13 TO 10 YEARS
AARDVARK THERAPEUTICS INC - TOPLINE DATA READOUT FOR TRIAL EXPECTED IN Q3 2026